Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

LCTX

STRONG SELL

Lineage Cell Therapeutics, Inc. · Healthcare · United States · $257M · Avg Vol: $2M/d

8
StockRank
Get insider-trade alerts
Q
28
V
25
M
29
P/E (TTM)
—
ROE
-98.2%
D/E
0.0x
Dividend %
—
Dir. Trades · 180d
+$24.4K →
Buybacks · 180d
None →
Loading 1Y...
PRICE (1Y)-18.9%
1.031.111.191.271.35Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$1.03
RSI (14)
16.3
52W High
$2.09
From 52W High
0.5%

SCORE BREAKDOWN

Quality
28
ROIC
-22.6%28.5
ROE
-98.2%9.2
GP/Assets
-3.7%8.1
Op. Margin
-440.2%10.6
FCF/Assets
-20.1%18.6
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.05x72.2
Current Ratio
6.89x79.6
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-9.2x25.0
P/FCF
—N/A
P/B
4.8x29.1
P/S
17.4x19.0
Div Yield
—N/A
Momentum
29
52W High %
49%25.5
RS 6M
-44%18.3
SMA 50/200
0.79x18.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+69%63.6
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$257M
P/E (Forward)
-11.4x
Gross Margin
99.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LCTX are excluded.

TickerCompanyMkt CapStockRankSignal
LCTXLineage Cell Therapeutics, Inc.(you)$257M8STRONG SELL
TTRXTurn Therapeutics Inc.$254M10STRONG SELL
TRDAEntrada Therapeutics, Inc.$227M8STRONG SELL
NMRANeumora Therapeutics, Inc.$276M10STRONG SELL
AVXLAnavex Life Sciences Corp.$222M9STRONG SELL
GALTGalectin Therapeutics Inc.$229M9STRONG SELL
OTLKOutlook Therapeutics, Inc.$263M11STRONG SELL
FHTXFoghorn Therapeutics Inc.$285M6STRONG SELL
RNACCartesian Therapeutics, Inc.$232M12STRONG SELL
TARAProtara Therapeutics, Inc.$226M12STRONG SELL

Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%

Lineage Cell Therapeutics, Inc. (LCTX) — Stock Score Summary

Lineage Cell Therapeutics, Inc. (LCTX) has a MoatMap StockRank of 8/100 based on Quality (28/100), Value (25/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price$1.03
Market Cap$257M
P/E (Forward)-11.44
Price/Book4.77
Return on Equity-98.2%
Return on Invested Capital-22.6%
Debt/Equity0.05x
Gross Margin99.0%
Operating Margin-440.2%
Revenue Growth14.8%
Free Cash Flow$-23M

Lineage Cell Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Lineage Cell Therapeutics, Inc.’s (LCTX) StockRank?
MoatMap’s StockRank for Lineage Cell Therapeutics, Inc. (LCTX) is 8/100, with a Strong Sell signal. It is a composite of Quality (28), Value (25), and Momentum (29) factor ranks across MoatMap’s 20,000+ stock universe.
Does Lineage Cell Therapeutics, Inc. have an economic moat?
Lineage Cell Therapeutics, Inc. (LCTX) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Lineage Cell Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Lineage Cell Therapeutics, Inc. (LCTX) is Strong Sell, based on a StockRank of 8/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Lineage Cell Therapeutics, Inc. in?
Lineage Cell Therapeutics, Inc. (LCTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksLCTX deep dive reportAI ChampionsHow we score stocksSense-check another stock